Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tatti, P.
Right arrow Articles by Strollo, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tatti, P.
Right arrow Articles by Strollo, F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 4 597-603, Copyright © 1998 by American Diabetes Association

ARTICLES

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM

P Tatti, M Pahor, RP Byington, P Di Mauro, R Guarisco, G Strollo and F Strollo
Centro Diabetico Ospedale di Marino, Italy.

OBJECTIVE: ACE inhibitors and calcium antagonists may favorably affect serum lipids and glucose metabolism. The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension. Prospectively defined cardiovascular events were assessed as secondary outcomes. RESEARCH DESIGN AND METHODS: Inclusion criteria included a diagnosis of NIDDM and hypertension (systolic blood pressure of > 140 mmHg or diastolic blood pressure of > 90 mmHg). Exclusion criteria included a history of coronary heart disease or stroke, serum creatinine > 1.5 mg/dl, albuminuria > 40 micrograms/min, and use of lipid-lowering drugs, aspirin, or antihypertensive agents other than beta-blockers or diuretics. A total of 380 hypertensive diabetics were randomly assigned to open-label fosinopril (20 mg/day) or amlodipine (10 mg/day) and followed for up to 3.5 years. If blood pressure was not controlled, the other study drug was added. RESULTS: Both treatments were effective in lowering blood pressure. At the end of follow-up, between the two groups there was no significant difference in total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin. The patients receiving fosinopril had a significantly lower risk of the combined outcome of acute myocardial infarction, stroke, or hospitalized angina than those receiving amlodipine (14/189 vs. 27/191; hazards ratio = 0.49, 95% CI = 0.26-0.95). CONCLUSIONS: Fosinopril and amlodipine had similar effects on biochemical measures, but the patients randomized to fosinopril had a significantly lower risk of major vascular events, compared with the patients randomized to amlodipine.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2009
Diabetes Care, January 1, 2009; 32(Supplement_1): S13 - S61.
[Full Text] [PDF]

Home page
 NEJMHome page
R. R. Holman, S. K. Paul, M. A. Bethel, H. A. W. Neil, and D. R. Matthews
Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
N. Engl. J. Med., October 9, 2008; 359(15): 1565 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
U.S. Preventive Services Task Force
Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement
Ann Intern Med, June 3, 2008; 148(11): 846 - 854.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
Y. Takata, H. Osawa, M. Kurata, M. Kurokawa, J. Yamauchi, M. Ochi, W. Nishida, T. Okura, J. Higaki, and H. Makino
Hyperresistinemia Is Associated With Coexistence of Hypertension and Type 2 Diabetes
Hypertension, February 1, 2008; 51(2): 534 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2008
Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
E. L. Air and B. M. Kissela
Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms
Diabetes Care, December 1, 2007; 30(12): 3131 - 3140.
[Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
A. D. Naik, T. T. Issac, R. L. Street Jr, and M. E. Kunik
Understanding the Quality Chasm for Hypertension Control in Diabetes: A Structured Review of "Co-maneuvers" Used in Clinical Trials
J Am Board Fam Med, September 1, 2007; 20(5): 469 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Ann Fam MedHome page
I. U. Park and A. L. Taylor
Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review
Ann. Fam. Med, September 1, 2007; 5(5): 444 - 452.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Yazdanpanah, Y. S. Aulchenko, A. Hofman, J. A.M.J.L. Janssen, F. A. Sayed-Tabatabaei, R. H.N. van Schaik, O. H. Klungel, B. H.C.H. Stricker, H. A.P. Pols, J. C.M. Witteman, et al.
Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes
Diabetes, July 1, 2007; 56(7): 1905 - 1912.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 Fam PractHome page
A. Siriwardena, P Fairchild, S Gibson, T Sach, and M Dewey
Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study
Fam. Pract., February 1, 2007; 24(1): 26 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2007
Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41.
[Full Text] [PDF]

Home page
 CirculationHome page
R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al.
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Circulation, March 14, 2006; 113(10): e409 - e449.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al.
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Stroke, February 1, 2006; 37(2): 577 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Cooper-DeHoff and C. J. Pepine
Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes
Eur. Heart J., January 1, 2006; 27(1): 5 - 6.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes-2006
Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. F.M. Strippoli, M. Craig, F. P. Schena, and J. C. Craig
Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy
J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3081 - 3091.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Hypertension in type 2 diabetes - targeting angiotensin
DTB, June 1, 2005; 43(6): 41 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al.
Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Arch Intern Med, April 25, 2005; 165(8): 936 - 946.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. J Epstein and J. G Gums
Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations
Ann. Pharmacother., March 1, 2005; 39(3): 470 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes
Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36.
[Full Text] [PDF]

Home page
 HypertensionHome page
G. L. Bakris, E. Gaxiola, F. H. Messerli, G. Mancia, S. Erdine, R. Cooper-DeHoff, C. J. Pepine, and for the INVEST Investigators
Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study
Hypertension, November 1, 2004; 44(5): 637 - 642.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. J. Pepine and R. M. Cooper-DeHoff
Cardiovascular therapies and risk for development of diabetes
J. Am. Coll. Cardiol., August 4, 2004; 44(3): 509 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J. Palmer, L. Annemans, S. Roze, M. Lamotte, P. Lapuerta, R. Chen, S. Gabriel, P. Carita, R. A. Rodby, D. de Zeeuw, et al.
Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease
Diabetes Care, August 1, 2004; 27(8): 1897 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. M. Sharma
Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Hypertension, July 1, 2004; 44(1): 12 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
K. M. Field, J. L. Pepin, and M. D. Mehta
Knowing When to Play the Ace: The Use and Under Use of Ace Inhibitors in Primary Practice
Journal of Pharmacy Practice, June 1, 2004; 17(3): 197 - 210.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. J. Lewis and J. B. Lewis
ACE Inhibitors versus Angiotensin Receptor Blockers in Diabetic Nephropathy: Is There a Winner?
J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1358 - 1360.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. Abbott, E. Basta, and G. L. Bakris
Blood Pressure Control and Nephroprotection in Diabetes
J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
C. M.M. Lawes, D. A. Bennett, V. L. Feigin, and A. Rodgers
Blood Pressure and Stroke: An Overview of Published Reviews
Stroke, April 1, 2004; 35(4): 1024 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
C. M.M. Lawes, D. A. Bennett, V. L. Feigin, and A. Rodgers
Blood Pressure and Stroke: An Overview of Published Reviews
Stroke, March 1, 2004; 35(3): 776 - 785.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. W. Durst and D. Schering
Hypertension Management in the Diabetes Patient
Journal of Pharmacy Practice, February 1, 2004; 17(1): 55 - 60.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. Trenkwalder
Antihypertensive treatment with calcium channel blockers: pharmacological pornography or useful intervention?
Nephrol. Dial. Transplant., January 1, 2004; 19(1): 17 - 20.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Standards of Medical Care in Diabetes
Diabetes Care, January 1, 2004; 27(90001): s15 - 35.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari
Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11.
[Abstract] [Full Text]

Home page
 J. Am. Soc. Nephrol.Home page
T. Berl
Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S71 - 76.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, B. Canaud, K.-U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali
The importance of diabetic nephropathy in current nephrological practice
Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1716 - 1725.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
P. Sleight
PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme
Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F40 - F47.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
S. Ross and M.-J. Macleod
Review: Hypertension in diabetes: a perspective from clinical pharmacology
The British Journal of Diabetes & Vascular Disease, July 1, 2003; 3(4): 252 - 256.
[Abstract] [PDF]

Home page
 Clin. DiabetesHome page
D. C. Goff Jr.
The ALLHAT Study
Clin. Diabetes, July 1, 2003; 21(3): 102 - 104.
[Full Text] [PDF]

Home page
 CMAJHome page
C. Stigant, L. Stevens, and A. Levin
Nephrology: 4. Strategies for the care of adults with chronic kidney disease
Can. Med. Assoc. J., June 10, 2003; 168(12): 1553 - 1560.
[Full Text] [PDF]

Home page
 JAMAHome page
B. M. Psaty, T. Lumley, C. D. Furberg, G. Schellenbaum, M. Pahor, M. H. Alderman, and N. S. Weiss
Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents: A Network Meta-analysis
JAMA, May 21, 2003; 289(19): 2534 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. H. Rosner and M. D. Okusa
Combination Therapy With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in the Treatment of Patients With Type 2 Diabetes Mellitus
Arch Intern Med, May 12, 2003; 163(9): 1025 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
N. R. Loon
Diabetic Kidney Disease: Preventing Dialysis and Transplantation
Clin. Diabetes, April 1, 2003; 21(2): 55 - 62.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. Berl, L. G. Hunsicker, J. B. Lewis, M. A. Pfeffer, J. G. Porush, J.-L. Rouleau, P. L. Drury, E. Esmatjes, D. Hricik, C. R. Parikh, et al.
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy
Ann Intern Med, April 1, 2003; 138(7): 542 - 549.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
V. Snow, K. B. Weiss, C. Mottur-Pilson, and for the Clinical Efficacy Assessment Subcommittee
The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus
Ann Intern Med, April 1, 2003; 138(7): 587 - 592.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. Vijan and R. A. Hayward
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care
Ann Intern Med, April 1, 2003; 138(7): 593 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. G. Douglas, G. L. Bakris, M. Epstein, K. C. Ferdinand, C. Ferrario, J. M. Flack, K. A. Jamerson, W. E. Jones, J. Haywood, R. Maxey, et al.
Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Arch Intern Med, March 10, 2003; 163(5): 525 - 541.
[Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
J. J. Saseen, E. J. MacLaughlin, and J. M. Westfall
Treatment of Uncomplicated Hypertension: Are ACE Inhibitors and Calcium Channel Blockers as Effective as Diuretics and {beta}-Blockers?
J Am Board Fam Med, March 1, 2003; 16(2): 156 - 164.
[Full Text] [PDF]

Home page
 HypertensionHome page
G. Mancia, M. Brown, A. Castaigne, P. de Leeuw, C. R. Palmer, T. Rosenthal, G. Wagener, and L. M. Ruilope
Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)
Hypertension, March 1, 2003; 41(3): 431 - 436.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Harris, K. Donahue, S. S. Rathore, P. Frame, S. H. Woolf, and K. N. Lohr
Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, February 4, 2003; 138(3): 215 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. D. Mooradian
Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines
Arch Intern Med, January 13, 2003; 163(1): 33 - 40.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. L Williams, A. Vazir, and A. G Zaman
Review: The management of stable angina in diabetes
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 18 - 25.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
M. Fisher
Prevention of macrovascular complications
Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B21 - B26.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
Standards of Medical Care for Patients With Diabetes Mellitus
Diabetes Care, January 1, 2003; 26(2007): S33 - S50.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Obesity, Hypertension, and Insulin Resistance
Diabetes Care, November 1, 2002; 25(11): 2088 - 2097.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Nosadini and G. Tonolo
Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus: The Role of Calcium Channel Blockers
J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S216 - 223.
[Abstract] [Full Text]